QuidelOrtho has signed a strategic supply agreement with Lifotronic Technology for expanding its global immunoassay portfolio, focusing on expediting access to high-throughput and low-to-mid volume immunoassay analysers.
The partnership aims to bring quality, cost-efficient, and scalable diagnostic solutions to selected international markets outside the US.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The immunoassay supply agreement is expected to enhance QuidelOrtho’s ability to compete in new regions.
It provides the company with access to several analysers supported by an extensive menu of assays, covering both routine and speciality testing.
The partnership will introduce over 25 new assays that are not offered on QuidelOrtho’s VITROS system, bringing the total number of available assays on these new platforms to more than 70.
These developments are intended to enable QuidelOrtho to fulfil broader tender requirements and address the needs of various laboratory environments.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataLaboratories ranging from those requiring low-volume solutions to larger settings needing scalable capacity and comprehensive test menus stand to benefit from this expanded offering.
The initiative will help address menu gaps and improve competitiveness in international tenders by offering laboratories more flexible system options.
QuidelOrtho’s global clinical laboratory and transfusion medicine senior vice-president Bryan Hanson said: “Through our collaboration with Lifotronic Technology, QuidelOrtho will rapidly introduce scalable testing solutions that further advance our long-term innovation strategy in core growth markets.
“This agreement strengthens our portfolio in markets where assay breadth and cost efficiency are key requirements, while offering customers a broader and more diverse set of solutions.”
In March 2024, QuidelOrtho announced that Health Canada had approved its Triage placental growth factor (PIGF) test for in-lab use.
